About Us

News

May 25, 2022

Neurocrine Biosciences Announces Repurchase of Convertible Notes
May 23, 2022

Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Data on Tardive Dyskinesia Improvement and Stability of Psychiatric Symptoms at American Psychiatric Association Annual Meeting 2022
May 12, 2022

Neurocrine Biosciences Receives Orphan Drug Designation for Valbenazine as a Treatment for Chorea Associated with Huntington Disease
May 4, 2022

Neurocrine Biosciences Reports First Quarter 2022 Financial Results and Reiterates 2022 Financial Guidance
May 3, 2022

Neurocrine Biosciences to Present at the Bank of America Securities 2022 Healthcare Conference
May 2, 2022

Neurocrine Biosciences Honors Mental Health Awareness Month and Fifth Anniversary of Tardive Dyskinesia Awareness Week
April 13, 2022

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2022 Financial Results
April 1, 2022

Neurocrine Biosciences Presents Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at AAN 2022
March 28, 2022

Neurocrine Biosciences Announces Regulatory Approval of Dysval® (valbenazine) for the Treatment of Tardive Dyskinesia in Japan
March 28, 2022

Neurocrine Biosciences to Present Data on Treatment Patterns and Unmet Needs in Adult and Pediatric Patients Living with Classic Congenital Adrenal Hyperplasia at AMCP 2022
Products

While others walk away from neuroscience because of risk and complexity, our team persists, resulting in four FDA-approved therapies.

Learn More
Leadership Team

Our mission to relieve patient suffering begins with our leadership team. They lead our effort to relentlessly pursue medicines to ease the burden of debilitating diseases and disorders.

Learn More